Dr. Reddy’s Divests Svaas Wellness Subsidiary in Small April 2026 Deal
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
On April 7, 2026, Dr. Reddy’s Laboratories signed an agreement to sell its entire shareholding in its wholly owned subsidiary Svaas Wellness Limited to Enspirit Technology Services Private Limited for INR 2.23 crore. The sale, which was completed the same day and is not a related-party or scheme-of-arrangement transaction, will see Svaas cease to be a subsidiary, though the unit contributed only about 0.09% of consolidated turnover in FY 2025, indicating minimal impact on group financials but a continued focus on portfolio rationalization.
The divestment of Svaas Wellness, whose FY 2025 turnover of Rs. 28.5 crore was entirely derived from Dr. Reddy’s, suggests the company is exiting a small, dependent operation to streamline its structure and reallocate capital to core or higher-priority assets. With the buyer unaffiliated with the promoter group and the transaction occurring entirely on April 7, 2026, the move underscores governance transparency while having limited direct impact on stakeholders given the subsidiary’s modest scale.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company focused on generic medicines, active pharmaceutical ingredients and related healthcare services. It operates across regulated markets including India and the U.S., with a strategy centered on scalable generics, specialty products and wellness offerings that complement its core formulations business.
Average Trading Volume: 2,098,349
Technical Sentiment Signal: Hold
Current Market Cap: $10.79B
Learn more about RDY stock on TipRanks’ Stock Analysis page.
